Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DACTINOMYCIN Cause Malignant neoplasm progression? 103 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 103 reports of Malignant neoplasm progression have been filed in association with DACTINOMYCIN (DACTINOMYCIN). This represents 3.6% of all adverse event reports for DACTINOMYCIN.

103
Reports of Malignant neoplasm progression with DACTINOMYCIN
3.6%
of all DACTINOMYCIN reports
50
Deaths
3
Hospitalizations

How Dangerous Is Malignant neoplasm progression From DACTINOMYCIN?

Of the 103 reports, 50 (48.5%) resulted in death, 3 (2.9%) required hospitalization, and 3 (2.9%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DACTINOMYCIN. However, 103 reports have been filed with the FAERS database.

What Other Side Effects Does DACTINOMYCIN Cause?

Off label use (391) Febrile neutropenia (226) Neutropenia (205) Product use in unapproved indication (203) Drug ineffective (181) Disease progression (151) Vomiting (119) Anaemia (109) Thrombocytopenia (106) Stomatitis (103)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which DACTINOMYCIN Alternatives Have Lower Malignant neoplasm progression Risk?

DACTINOMYCIN vs DALBAVANCIN DACTINOMYCIN vs DALFAMPRIDINE DACTINOMYCIN vs DALTEPARIN DACTINOMYCIN vs DAMOCTOCOG ALFA PEGOL DACTINOMYCIN vs DANAPAROID

Related Pages

DACTINOMYCIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression DACTINOMYCIN Demographics